As of 02 May 2025, the Health Technology Assessment (HTA) Council has completed the evidence appraisal on the assessment of ticagrelor [90mg film-coated tablet] as an add-on to aspirin for adults with acute coronary syndrome (ACS) for possible financing by the Department of Health (DOH) and/or the Philippine Health Insurance Corporation (PhilHealth). The HTA Council continue reading : HTA Council Preliminary Recommendation on ticagrelor [90mg film-coated tablet] as an add-on to aspirin for adults with acute coronary syndrome (ACS)
HTA Council Preliminary Recommendation on Tetanus, Diptheria, and Acellular Pertussis (Tdap) Vaccine as booster immunization against tetanus, diptheria, and pertussis for Grade 1 students (6-7 years old, Grade 7 students (11-12 years old) and pregnant women
As of 02 May 2025, the Health Technology Assessment (HTA) Council has completed the evidence appraisal on the assessment of Tetanus, Diphtheria, and Acellular Pertussis (Tdap) Vaccine as booster immunization against tetanus, diphtheria, and pertussis for Grade 1 students (6-7 years old), Grade 7 students (11-12 years old) and pregnant women for possible government financing. continue reading : HTA Council Preliminary Recommendation on Tetanus, Diptheria, and Acellular Pertussis (Tdap) Vaccine as booster immunization against tetanus, diptheria, and pertussis for Grade 1 students (6-7 years old, Grade 7 students (11-12 years old) and pregnant women
HTA Council Preliminary Recommendation on Hexavalent Vaccine for active immunization of infants to prevent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis b, and invasive disease due to Haemophilus influenzae type b
As of 05 March 2025, the Health Technology Assessment (HTA) Council makes public its preliminary recommendation on the non-inclusion in the PNF and thus the non-government financing of hexavalent vaccine, for stakeholder feedback/comments. Overall, the HTA Council recognizes that hexavalent vaccines will result in a simpler immunization schedule and thus, better compliance and easier implementation. continue reading : HTA Council Preliminary Recommendation on Hexavalent Vaccine for active immunization of infants to prevent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis b, and invasive disease due to Haemophilus influenzae type b
HTA Council Preliminary Recommendation on Abacavir/Lamivudine Tablet, Levonorgestrel Intrauterine Delivery (IUD) System, Levonorgestrel Subdermal Implant, Multiple Micronutrient Supplement Capsule, and Sodium Chloride + Potassium Chloride + Calcium Lactate Pentahydrate Powder for Reconstitution
Update as of 25 November 2024 : Since the public consultation and appeals period for the HTA Council Preliminary Recommendation on Abacavir/Lamivudine Tablet, Levonorgestrel Intrauterine Delivery (IUD) System, Levonorgestrel Subdermal Implant, Multiple Micronutrient Supplement Capsule, and Sodium Chloride + Potassium Chloride + Calcium Lactate Pentahydrate Powder for Reconstitution ended on 22 November 2024 without valid appeals received, this continue reading : HTA Council Preliminary Recommendation on Abacavir/Lamivudine Tablet, Levonorgestrel Intrauterine Delivery (IUD) System, Levonorgestrel Subdermal Implant, Multiple Micronutrient Supplement Capsule, and Sodium Chloride + Potassium Chloride + Calcium Lactate Pentahydrate Powder for Reconstitution
HTA Council Preliminary Recommendation on Dapivirine Vaginal Ring, Donepezil Hydrochloride, Tenofovir/Lamivudine/Dolutegravir and Tenofovir + Lamivudine in combination with Dolutegravir
Update as of 06 November 2024 : Since the public consultation and appeals period for the HTA Council Preliminary Recommendation on Dapivirine Vaginal Ring, Donepezil Hydrochloride, Tenofovir/Lamivudine/Dolutegravir and Tenofovir + Lamivudine in combination with Dolutegravir ended on 05 November 2024 without appeals received, this preliminary HTA Council recommendation lapsed into the Final Recommendation and was transmitted to the Secretary of continue reading : HTA Council Preliminary Recommendation on Dapivirine Vaginal Ring, Donepezil Hydrochloride, Tenofovir/Lamivudine/Dolutegravir and Tenofovir + Lamivudine in combination with Dolutegravir